Galantamine is a naturally derived alkaloid and a well-established therapeutic agent primarily used in the management of mild to moderate Alzheimer’s disease. It works by inhibiting acetylcholinesterase and modulating nicotinic receptors, thereby enhancing cholinergic neurotransmission and improving cognitive function. The history of galantamine dates back to the mid-20th century when it was first isolated from plants such as Galanthus (snowdrop) species and later from other members of the Amaryllidaceae family. Initially studied for its effects on the nervous system, galantamine gained clinical importance as understanding of Alzheimer’s disease advanced and the role of acetylcholine deficiency became clear. Over time, it was developed into a standardized pharmaceutical formulation, received regulatory approvals worldwide, and became an important option in dementia treatment due to its dual mechanism of action and favorable efficacy profile.
